Quinoline derivatives as bromodomain inhibitors
US-2015148344-A1 · May 28, 2015 · US
US11117865B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11117865-B2 |
| Application number | US-201916442526-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 16, 2019 |
| Priority date | Dec 16, 2016 |
| Publication date | Sep 14, 2021 |
| Grant date | Sep 14, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, having Formula III: wherein: R 11 , R 12 , and R 13 are independently H, —OH, halogen, alkoxy, —NH 2 , —CF 3 , —(CO)R 17 where R 17 is alkyl, alkoxy, amino, or alkylamino; R 14 is a C1-4 alkyl substituted with one or more of OH, alkoxy, amino, alkylamino, or an unsubstituted 5-6 membered heterocycle with 1-3 heteroatoms. 2. The compound of claim 1 , wherein the compound is selected from compound having a structure of 3. The compound of claim 2 , wherein the compound has a structure of; 4. A compound, or a pharmaceutically acceptable salt thereof, having the Formula IIIa: wherein: R 11 , R 12 , and R 13 are independently H, —OH, halogen, alkoxy, —NH 2 , —CF 3 , —(CO)R 17 where R 17 is alkyl, alkoxy, amino, or alkylamino; R 15 is H, —OH, alkyl, or NH 2 ; p is 0-4; R 16 is H, —OH, alkyl, alkoxy; or —NR 18 R 19 where R 18 and R 19 are independently H, alkyl; or R 18 and R 19 are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms; wherein at least one of R 11 , R 12 , or R 13 is —OH, halogen, alkoxy, —NH 2 , —CF 3 , —(CO)R 17 when R 15 is H, and R 16 is H or alkyl.
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.